Ancient proteins outperform modern antibodies against drug-resistant bacteria

Scientists at the University of Oregon have begun mining an unlikely archive for solutions to one of medicine's most pressing problems: the evolutionary record of extinct mammals. By reconstructing proteins that existed 160 million years ago, researchers discovered that some ancient antimicrobial peptides outperformed their modern human counterparts when tested against bacteria resistant to current drugs. The work, published in PLOS Biology in August, suggests that nature's long experiment with infection defense holds practical lessons for designing the next generation of treatments.

The study centered on lactoferrin, an immune protein present in nearly every body fluid except blood—breast milk, tears, saliva, intestinal mucus. Scientists have long known it works partly by binding iron, starving bacteria of a nutrient they need to survive. But lactoferrin contains something else: a short antimicrobial peptide embedded within the larger protein that attacks bacterial membranes directly, punching holes that can kill or disable microbial cells. The researchers wanted to trace when this capability first appeared and how it evolved as mammals diversified over millions of years. Their investigation led them back to the earliest ancestors of placental mammals, the group that would eventually produce humans and most living mammals today.

To see what these ancient proteins actually looked like, the team used genetic sequences from living animals—humans, cows, and others—to map lactoferrin's evolutionary relationships. Using ancestral sequence reconstruction, they predicted what the protein's genes might have resembled millions of years in the past. They synthesized these predicted genes and produced the reconstructed proteins in the laboratory. When tested against disease-causing bacteria including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Streptococcus, the oldest reconstructed peptides could damage bacterial membranes but often failed to kill the cells outright—bacteria frequently repaired the damage and survived. As the researchers moved forward through evolutionary time, however, the peptides grew progressively more effective. Some versions from relatively recent mammalian ancestors proved more potent against certain drug-resistant bacteria than the peptides found in modern humans.

One of the study's most striking findings was how little genetic change sometimes produced dramatic shifts in antimicrobial power. A single mutation in the amino-acid sequence could substantially boost a peptide's ability to attack bacteria. This observation reframes evolution from a historical curiosity into something more useful: a vast catalogue of natural experiments, documenting which molecular changes succeeded and which failed over hundreds of millions of years. For researchers seeking new drug designs, that archive becomes a reference library of what works.

Yet the researchers are careful about expectations. Ancient peptides are not ready to replace antibiotics. Antimicrobial peptides tend to be less structurally stable than conventional drugs and break down quickly inside the human body. Their immediate value lies instead in serving as blueprints—templates that show which structural features make a peptide effective against bacteria. By studying how evolution refined these defenses, the team identified specific modifications that enhanced potency. Those insights could guide the design of new molecules engineered to work alongside existing antibiotics. The approach may also help scientists anticipate how bacteria might develop resistance to future antimicrobial agents. Understanding the strengths and weaknesses of these ancient biological weapons could eventually enable researchers to develop therapies that are harder for pathogens to evade. In the escalating struggle against drug-resistant infections, the distant past offers not a forgotten cure waiting to be revived, but a blueprint for building better ones.